- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
WARS Antibody (monoclonal) (M02)Purified Mouse Monoclonal Antibody (Mab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AT4524a | 100 ug 400 ul | 7-10 days | $ 315.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
WARS Antibody (monoclonal) (M02) - Product info | |
| Application | IF, WB
|
| Primary Accession | P23381 |
| Other Accession | NP_004175 |
| Reactivity | Human |
| Concentration | 1 mg/ml |
| Isotype | IgG2a Kappa |
| Clone Names | 3A12 |
| Calculated MW | 53165 Da |
WARS Antibody (monoclonal) (M02) - Additional info | |
| Gene ID 7453 | |
| Other Names GAMMA2, IFI53, IFP53tryptophanyl-tRNA synthetase | |
| Target/Specificity WARS (NP_004175, 50 a.a. ~ 150 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. | |
| Dilution WB~~1:500~1000 | |
| Format Clear, colorless solution in phosphate buffered saline, pH 7.2 . | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions WARS Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures. | |
WARS Antibody (monoclonal) (M02) - Related products
AP2934a: WARS Antibody (N-term)
WARS Antibody (monoclonal) (M02) - Application data
-
Immunofluorescence of monoclonal antibody to WARS (AT4524a) on HeLa cell . [antibody concentration 10 ug/ml]
-
WARS monoclonal antibody (M02), clone 3A12 Western Blot analysis of WARS expression in HeLa ( Cat # L013V1 ).
WARS Antibody (monoclonal) (M02) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Two forms of tryptophanyl-tRNA synthetase exist, a cytoplasmic form, named WARS, and a mitochondrial form, named WARS2. Tryptophanyl-tRNA synthetase (WARS) catalyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by interferon. Tryptophanyl-tRNA synthetase belongs to the class I tRNA synthetase family. Four transcript variants encoding two different isoforms have been found for this gene.
REFERENCES
Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Talmud PJ, et al. Am J Hum Genet, 2009 Nov. PMID 19913121.The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Ghanipour A, et al. Cancer Epidemiol Biomarkers Prev, 2009 Nov. PMID 19900940.Allostery and conformational free energy changes in human tryptophanyl-tRNA synthetase from essential dynamics and structure networks. Bhattacharyya M, et al. Proteins, 2010 Feb 15. PMID 19768679.Increased TTS abrogates IDO-mediated CD4(+) T cells suppression in patients with Graves' disease. Wang S, et al. Endocrine, 2009 Aug. PMID 19363598.